Image of the Day: Patient-Derived Organoids
Image of the Day: Patient-Derived Organoids

Image of the Day: Patient-Derived Organoids

Three-dimensional tissue cultures grown from cancer patients’ own tumors can predict responses to the drug irinotecan.

Oct 10, 2019
Emily Makowski

ABOVE: Brightfield microscopy image of patient-derived organoids in culture
S.N. OOFT AND M. MERTZ

Researchers have developed a method of testing 3-D tissue cultures called organoids from colorectal cancer patients’ tumors for whether the cancer will respond to chemotherapy. Emile Voest, a professor of oncology and the medical director of the Netherlands Cancer Institute, and colleagues published a paper in Science Translational Medicine yesterday (October 9) on their findings. The team procured tumor biopsies from 61 patients with metastatic colorectal cancer and used the samples to generate organoids, which were then treated with different chemotherapy drugs, either irinotecan or 5-fluorouracil combined with irinotecan or oxaliplatin.

Organoid image taken with phase-contrast microsopy
S.N. OOFT AND M. MERTZ

The organoid response to irinotecan, measured by organized growth rates, correctly predicted how 80 percent of the patients reacted to the drug. The assay could not predict the 5-fluorouracil treatments.

These findings suggest that this personalized medicine technique could detect tumors that will be nonresponsive to irinotecan treatments and prevent colorectal cancer patients from being unnecessarily medicated with the drug. Additionally, the organoids were grown and screened within three weeks, a vast improvement over the 2–6 months it takes to test other cell culture models, the authors write in the paper.

S.N. Ooft et al., “Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients,” Sci Transl Med, doi:10.1126/scitranslmed.aay2574, 2019.

Emily Makowski is an intern at The Scientist. Email her at emakowski@the-scientist.com.